Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
Bio Pharma Dive
APRIL 22, 2024
billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Bio Pharma Dive
APRIL 22, 2024
billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8
Pharmaceutical Technology
APRIL 22, 2024
Discover how Silence Therapeutics' patented compound for RNA interference therapy targets liver disease with precision. Learn about the specific chemical formula and potential therapeutic benefits outlined in the recently granted patent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 22, 2024
bn alliance with Skyhawk Therapeutics focused on RNA-modulating drugs for rare neurological diseases. Ipsen agrees $1.8
Pharmaceutical Technology
SEPTEMBER 9, 2022
US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Gatehouse Bio is engaged in developing small RNA-based therapeutics using AI technology.
Pharmaceutical Technology
AUGUST 3, 2023
AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.
Bio Pharma Dive
JANUARY 3, 2024
The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.
Bio Pharma Dive
SEPTEMBER 6, 2022
A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers.
Bio Pharma Dive
SEPTEMBER 5, 2023
The biotech, one of several advancing RNA editing medicines, expects to obtain “proof-of-mechanism” data in patients with the inherited disorder alpha-1 antitrypsin deficiency by next year.
Pharmaceutical Technology
MAY 23, 2023
ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”
Bio Pharma Dive
AUGUST 23, 2022
At least 10 biotechnology startups are trying to use RNA molecules in new ways to make medicines. Here’s a look at where they stand.
Bio Pharma Dive
AUGUST 30, 2021
Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus.
Bio Pharma Dive
JULY 25, 2022
The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.
pharmaphorum
MARCH 25, 2024
billion, adding expertise in RNA therapeutics and a heart failure therapy in mid-stage trials. Novo Nordisk has agreed to buy Cardior Pharmaceuticals for $1.1
BioSpace
APRIL 21, 2024
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
Bio Pharma Dive
NOVEMBER 9, 2021
The biotech is researching how to make medicines from transfer RNA molecules. Encouraged by Moderna's success, Flagship Pioneering has been busy creating startups like Alltrna, which launched Tuesday.
Bio Pharma Dive
OCTOBER 12, 2022
The startup, run by Translate Bio cofounder Romesh Subramanian, believes its RNA “exon editing” approach could have long-lasting effects without the risks that come with editing DNA.
Pharmaceutical Technology
JUNE 1, 2023
A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. It will focus on studying and developing new lipid nanoparticle (LNP) formulations for the delivery of RNA medicine.
Bio Pharma Dive
SEPTEMBER 7, 2022
“We see a huge opportunity in the setting of RNA-based therapies to overcome some of the shortcomings that have been there with the first generation of RNA companies,” said former Alnylam CEO and Orbital Therapeutics co-founder John Maraganore.
Bio Pharma Dive
MAY 10, 2021
Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines.
Pharmaceutical Technology
MARCH 1, 2023
Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.
Pharmaceutical Technology
DECEMBER 13, 2023
Daiichi Sankyo plans to leverage the French startup’s technology to develop its RNA-targeted therapeutics pipeline.
Bio Pharma Dive
JANUARY 11, 2022
Arrakis, a specialist in designing oral drugs that target RNA, will receive $75 million under the deal, which could be worth "several billion dollars" more.
Pharmaceutical Technology
JUNE 16, 2023
from Flanders Innovation & Entrepreneurship (VLAIO) to further advance its oncology portfolio targeting RNA. It will also support the firm’s preclinical effort on the long non-coding RNA (LncRNA) programme, FTX-001, that targets MALAT-1. Flamingo Therapeutics has received a research grant of €1.7m
Bio Pharma Dive
JULY 6, 2021
The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs.
BioSpace
DECEMBER 3, 2023
From the skin to the lungs to the central nervous system, biotech companies are making progress toward delivering RNA therapeutics to multiple targets throughout the body. But challenges remain.
Pharmaceutical Technology
NOVEMBER 13, 2023
Heqet Therapeutics and Ethris have collaborated to develop RNA-based therapeutics to treat cardiovascular conditions.
Pharmaceutical Technology
APRIL 27, 2023
Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.
Bio Pharma Dive
MAY 23, 2023
Staffed by many former Alnylam and Moderna employees, the startup is developing technologies that could be useful in a variety of RNA drugmaking methods.
Pharmaceutical Technology
NOVEMBER 2, 2023
While things may have slowed down a little since the rapid approvals of the COVID-19 vaccines, the excitement around RNA-LNP is still going strong.
Bio Pharma Dive
SEPTEMBER 8, 2021
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen.
pharmaphorum
APRIL 12, 2024
Join 80+ technical experts from the likes of AstraZeneca, Atavistik Bio, AbbVie, NextRNA Therapeutics, Expansion Therapeutics, Accent Therapeutics and more at the 2nd RNA Assay Development & Screening Summit 2024.
Bio Pharma Dive
FEBRUARY 17, 2022
The agreement with the Cambridge-based startup is the latest to reflect growing large pharma company interest in targeting RNA with small molecules.
Pharmaceutical Technology
OCTOBER 11, 2022
Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.
pharmaphorum
NOVEMBER 29, 2023
Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower dose.
BioSpace
OCTOBER 8, 2023
Its reversible nature offers the potential for RNA editing to go beyond rare diseases, eliciting excitement and buy-in from large pharmas like GSK and Eli Lilly.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 1, 2023
The Drug Controller General of India (DCGI) has added in-vitro diagnostic (IVD) medical devices including those for diagnosis of Covid-19, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) extraction kits, among others into the Class C risk category under the Medical Devices Rules (MDR), 2017.
BioSpace
OCTOBER 15, 2023
The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.
Pharmaceutical Technology
MAY 11, 2023
Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.
pharmaphorum
DECEMBER 13, 2023
Daiichi Sankyo taps Depixus to speed RNA drug discovery Phil.Taylor Wed, 13/12/2023 - 10:43 Bookmark this
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.
Drug Discovery World
SEPTEMBER 18, 2023
Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ Join this free roundtable to learn about challenges related to the delivery of RNA therapeutics and some of factors advancing research in this field. What does the RNA pipeline look like across disease areas?
Pharmaceutical Technology
JULY 29, 2022
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Their platform identifies which regRNAs control the specific gene of interest.
pharmaphorum
DECEMBER 8, 2023
The 3rd Next Generation RNA Therapeutics Summit returns to Boston this May 2024 to cover the depth and breadth of the next generation of RNAs
Bio Pharma Dive
JANUARY 6, 2021
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content